GV, Northpond Ventures and Sanofi Ventures have joined forces to pump $100 million into OMass Therapeutics, teeing the British biotech up to advance candidates against hard-to-hit targets toward the clinic. CEO Ros Deegan frames OMass’ platform as a way to give fidelity and precision, rather than having to decide between the two. The traditional trade-off is faced across two current approaches—cell and cell-free. Cell-free shows precisely how a molecule interacts with a target but is stripped of other elements, such as endogenous regulatory molecules, that could influence the interaction in vivo. A cell-based approach retains those other elements, but this adds confounding factors. Source: Fierce Biotech 28/4/22